Nemaura Medical's Program Shows Weight Loss In 100% Of Participants

Vandana Singh
1 min read
0
In this article:

  • Nemaura Medical Inc (NASDAQ: NMRD) has announced initial results from patient studies of its metabolic health program Miboko with the National Health Service (NHS) in the U.K.

  • The initial pilot program recruited 30 individuals classified as obese according to their BMI.

  • The first cohort of 10 patients enrolled in the program for over 12 weeks.

  • Results from this cohort indicate that these individuals achieved an average weight loss of 3.7 pounds and an average BMI improvement of 0.6 after 10 weeks, with 100% of participants achieving some weight improvement.

  • Participants' feedback shows that the body-worn sensor's use led to greater engagement and an element of gamification that is anticipated to lead to sustained use and encourage incremental dietary and lifestyle changes through a combination of personalized data and targeted education modules.

  • Participants expressed their willingness to continue with the program.

  • The Miboko program is the first to integrate a daily-wear non-invasive glucose sensor with a lifestyle app, which includes a recording of food and drink, educational content, and an analytics platform.

  • Price Action: NMRD shares are up 4.46% at $2.21 on the last check Tuesday.

  • Photo Via Company

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article originally appeared on Benzinga.com

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories